Curvus Announces 510(K) Clearance of its Completely Wireless Arrhythmia Monitoring Device.

Borge Bogaard, Chief Executive Officer of Curvus, said, "We are thrilled that Curvus has achieved regulatory clearance and can now be commercialized in the US. Due to the rapidly increasing burden of atrial fibrillation worldwide, we believe that expanded monitoring and diagnosis of these cardiac events combined with the release of several new anticoagulant drugs, will make a major contribution to control the disastrous worldwide burden of stroke. With its 100% wireless design and ability to transmit clear, actionable data whether the patient is resting, running a marathon or showering, we believe Curvus is well-positioned to expand monitoring broadly."